Accolade vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Accolade is a personalized health and benefits navigation platform that provides employers with dedicated health assistants who help employees navigate care and benefits.
About
Accolade is a publicly traded health advocacy company founded in 2007 that provides employers with a personalized health and benefits assistance platform combining human health assistants with data analytics and clinical expertise. The company's advocates help employees understand their benefits, find appropriate providers, navigate complex diagnoses, and access mental health support through a high-touch model that traditional health plan member services cannot match. Accolade serves large employers as a white-labeled benefit that creates a personalized experience for each employee, with advocates who maintain ongoing relationships rather than routing calls to anonymous call centers. The company is publicly traded on Nasdaq under ACCD and has acquired PlushCare, a virtual primary care platform, and 2nd.MD, an expert medical opinion service, to integrate clinical care alongside navigation. Accolade has demonstrated measurable ROI for employer customers through reduced emergency department visits, better management of chronic conditions, and improved benefits utilization. The company serves over 3 million covered lives and positions itself as a whole-person health solution that improves outcomes while lowering costs for self-insured employers.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.